July 9 (Reuters) – Moderna said on Thursday it has secured a European Commission contract to supply its respiratory syncytial virus vaccine to six countries in the region.
Here are the details:
• The agreement gives the participating countries – Austria, Denmark, Ireland, Luxembourg, Norway and Portugal – access to up to 24 million doses of the vaccine over as many as four years, the company said.
• The vaccine, mRESVIA, will be supplied in a ready-to-use, single-dose pre-filled syringe, making administration easier for healthcare professionals, Moderna said.
• The company had a similar joint procurement framework agreement with the European Commission for COVID-19 vaccines last year.
• mRESVIA is authorized in the European Union to prevent lower respiratory tract disease caused by RSV in adults.
• RSV is a common respiratory virus that causes seasonal infections such as the flu and is a leading cause of pneumonia and death in infants and older adults.
• Moderna has four approved mRNA vaccines for respiratory infections, including a combined influenza and COVID-19 vaccine authorized in Europe.
(Reporting by Christy Santhosh in Bengaluru; Editing by Leroy Leo)
